ArticleJAC-antimicrobial resistance2026
Sustained chlorhexidine susceptibility in clinical MRSA isolates despite recent exposure.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: MRSA decolonization strategies are widely implemented to reduce the risk of invasive infections but rely heavily on the use of chlorhexidine. Reduced chlorhexidine susceptibility has been reported after widespread use in hospital settings. The objective of the study is to assess chlorhexidine susceptibility among clinical MRSA isolates and to investigate potential induction of reduced susceptibility following chlorhexidine exposure. Methods: Ninety-five MRSA isolates from 77 patients of the University Hospital Zurich, treated between October 2021 and September 2022, were included. Chlorhexidine MICs were determined using the broth microdilution method, and subsequently MBCs were assessed. WGS was performed using the Illumina technology. Ten isolates with MBC values ≥8 mg/L were selected for cyclic exposure experiments using sub-inhibitory chlorhexidine concentrations and for analysis of genes associated with reduced chlorhexidine susceptibility. Longitudinal isolates from seven patients were analysed to assess in-host evolution. Results: Most isolates showed chlorhexidine MICs of 2 mg/L (76.6%, 60/77) and MBCs of 4 mg/L (68.8%, 53/77). ST8 was the most represented MLST among the isolates tested (23.1%). None of the 10 isolates with MBCs ≥8 mg/L demonstrated further reductions in chlorhexidine susceptibility following repeated sub-lethal exposure. Although resistance-associated genes were detected, no phenotypic impact on chlorhexidine susceptibility was observed. Longitudinal analysis of seven patients revealed stable MIC and MBC values despite prolonged carriage and chlorhexidine exposure. Conclusions: These findings indicate the absence of inducible or clinically relevant reduced susceptibility to chlorhexidine among MRSA isolates in this setting, despite repeated exposure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.